Welcome to LookChem.com Sign In|Join Free

CAS

  • or

19757-64-3

Post Buying Request

19757-64-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

19757-64-3 Usage

General Description

N-Cyclopropylurea is a chemical compound that belongs to the group of urea derivatives. It is a white crystalline solid with a molecular formula of C4H7N3O, and is used for various chemical and pharmaceutical applications. N-Cyclopropylurea has been identified as a potent inhibitor of solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), and has potential therapeutic applications in the treatment of hyperuricemia and related disorders. It is also used as a building block in the synthesis of pharmaceuticals and agrochemicals. Additionally, N-Cyclopropylurea may have potential applications in the development of new materials and organic synthesis processes.

Check Digit Verification of cas no

The CAS Registry Mumber 19757-64-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,7,5 and 7 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 19757-64:
(7*1)+(6*9)+(5*7)+(4*5)+(3*7)+(2*6)+(1*4)=153
153 % 10 = 3
So 19757-64-3 is a valid CAS Registry Number.
InChI:InChI=1/C4H8N2O/c5-4(7)6-3-1-2-3/h3H,1-2H2,(H3,5,6,7)

19757-64-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name cyclopropylurea

1.2 Other means of identification

Product number -
Other names 1-cyclopropylurea

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:19757-64-3 SDS

19757-64-3Relevant articles and documents

Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells

Liu, Yao,Zhen, Yongqi,Wang, Guan,Yang, Gaoxia,Fu, Leilei,Liu, Bo,Ouyang, Liang

, (2020)

Eukaryotic elongation factor 2 kinase (eEF2K) is a key α-kinase that negatively regulates the extension step of protein synthesis, which consumes most of the energy and amino acids required for protein synthesis. Studies have found that eEF2K protein is related to the breast cancer. However, existing inhibitor effect has not achieved the desired effect in cancer therapy. Proteolysis target chimeric (PROTAC) technology is uses proteasome to degrade target protein to achieve the purpose of inhibiting tumour cell growth. Here, we reported that the use of PROTAC strategy in combining with star eEF2K inhibitor A484954 and its potential derivatives. Consequently, candidate compound 11l was found to degrade eEF2K and induce apoptosis in human breast carcinoma MDA-MB-231 cells. Together, these findings demonstrate that our eEF2K-targeting PROTAC small molecule would be a potential new strategy for future breast cancer therapy.

Novel quinoline derivative inhibitor

-

Paragraph 0912; 0914-0916, (2020/03/12)

The invention provides a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). According to the invention, the compound provided by the invention can selectively inhibit tyrosine kinase TAM family/an

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

-

, (2008/06/13)

Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula STR1 where R1 and R3 are identical or different and at least one of the radicals R1 and R3 is a radical of the formula XI STR2 in which E is a covalent bond or a (C1 -C5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 19757-64-3